Phase I, Open-Label, Multicentre, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of A Single Intravenous PPMX-T003 in Polycythemia Vera
Latest Information Update: 13 Oct 2024
At a glance
- Drugs PPMX-T003 (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions
- Sponsors Perseus Proteomics
- 12 Dec 2023 Interim results (n=3; data cutoff date: Jun 2023) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 21 Jul 2023 Planned End Date changed from 1 Oct 2023 to 31 Mar 2024.
- 29 Aug 2022 Planned primary completion date changed from 1 Oct 2023 to 1 Aug 2023.